Affiliation:
1. Federal State Budgetary Educational Institution of Further Professional Education «Russian Medical Academy of Continuing Professional Education» of the Ministry of Health of the Russian Federation.
2. Coronary and Vascular Surgery Institute of the Federal State Budgetary Institution «Bakulev National Medical Research Center for Cardiovascular Surgery» of the Ministry of Health of the Russian Federation.
3. State Budgetary Healthcare Institution of Moscow «Sklifosovsky Research Institute of Emergency Medicine of the Department of Health of Moscow».
Abstract
The article discusses approaches to the choice of antihypertensive drugs, which may be based on the adoption and implementation of new clinical guidelines for the management of patients with arterial hypertension. This paper provides data on the efficacy and safety of candesartan, an antihypertensive drug, which advantages were identified during a large number of randomized clinical trials. It discusses the recently published data on the effectiveness of more intensive regimens of antihypertensive therapy to reduce the risk of moderate cognitive impairment in patients with arterial hypertension. In this regard, the authors provide data of the previously completed studies, which showed the effect of candesartan on the rate of cognitive decline in patients with arterial hypertension in the elderly and senile age. The features of the pharmacological characteristics of candesaratan that can remotely explain its clinical efficacy are considered. The data of experimental studies of candesartan in animals, which contribute to the concept of the possible effects of candesartan, are presented.
Reference17 articles.
1. Williams B., Mancia G., Spiering W. et al. 2018 ESC/ESH Guidelines for the management of arterial hypertension. Eur Heart J. 2018 Sep 1;39(33):3021-3104. doi: 10.1093/eurheartj/ ehy339.
2. Whelton P.K., Carey R.M., Aronow W.S. et al. 2017. ACC/AHA/AAPA/ABC/ACPM/AGS/APhA/ ASH/ASPC/NMA/PCNA Guideline for the Prevention, Detection, Evaluation, and Management of High Blood Pressure in Adults. Hypertension. 2018;71:e13-e115. doi: 10.1161/ HYP.0000000000000065. 2017.
3. SPRINT Research Group. A Randomized Trial of Intensive versus Standard Blood-Pressure Control. N Engl J Med. 2015;373:2103-2116.
4. Phillips R.A., Xu J., Peterson L.E. et al. Impact of Cardiovascular Risk on the Relative Benefit and Harm of Intensive Treatment of Hypertension. J Am Coll Cardiol. 2018;71:1601-1610. doi: 10.1016/j.jacc.2018.01.074.
5. Julius S., Nesbitt S.D., Egan B.M. et al. Feasibility of treating prehypertension with an angiotensinreceptor blocker. N Engl J Med. 2006;354:1685-1697.